Genocea Doses First Patient in Phase 1/2a TiTAN Clinical Trial for GEN-011 Neoantigen-Targeted T cell Therapy
July 13, 2021 07:30 ET
|
Genocea Biosciences, Inc.
CAMBRIDGE, Mass., July 13, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced the...
Genocea Presents Promising Long-term Results from GEN-009 Neoantigen Vaccine Phase 1 Trial at ASCO 2021
June 04, 2021 09:00 ET
|
Genocea Biosciences, Inc.
Four of nine checkpoint inhibitor-sensitive patients experienced RECIST responses post vaccination; median duration without disease progression after initial GEN-009 vaccination was 15 months Two of...
Genocea Provides First Quarter 2021 Corporate Update
April 29, 2021 07:00 ET
|
Genocea Biosciences, Inc.
GEN-011 and GEN-009 immuno-oncology programs continue to advance Research on Inhibigens™ and SARS-CoV-2 continues to progress Conference call today at 8:30 a.m. E.T. CAMBRIDGE, Mass., April ...
Genocea To Host First Quarter 2021 Corporate Update Conference Call & Webcast
April 22, 2021 16:30 ET
|
Genocea Biosciences, Inc.
CAMBRIDGE, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its first...
Genocea to Present Novel Preclinical Inhibigen™ Data at AACR Annual Meeting 2021
April 10, 2021 08:30 ET
|
Genocea Biosciences, Inc.
Pro-tumor effects detected as early as four days after Inhibigen administration Insights into Inhibigen biology may yield new therapeutic targets to address immunotherapy resistance ...
Genocea to Present at the 20th Annual Needham Virtual Healthcare Conference
April 06, 2021 16:30 ET
|
Genocea Biosciences, Inc.
CAMBRIDGE, Mass., April 06, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that...
Genocea to Present at the H.C. Wainwright Global Life Sciences Conference
March 02, 2021 16:01 ET
|
Genocea Biosciences, Inc.
CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that...
Genocea Provides Fourth Quarter 2020 Corporate Update
February 11, 2021 07:30 ET
|
Genocea Biosciences, Inc.
GEN-011 and GEN-009 clinical trials continue to advance ATLASTM stimulatory antigen and inhibitory antigen (InhibigenTM) identification profiled in Cancer Discovery Announcing SARS-CoV-2 T cell...
Genocea to Host Fourth Quarter 2020 Corporate Update Conference Call & Webcast
February 04, 2021 16:05 ET
|
Genocea Biosciences, Inc.
CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host its fourth...
Genocea Announces Publication in Cancer Discovery Highlighting the Advantages of Neoantigen Identification with the ATLAS™ Platform
January 28, 2021 06:00 ET
|
Genocea Biosciences, Inc.
Study validates ATLAS bioassay for developing patient-specific cancer immunotherapies by including neoantigensof anti-tumor T cell responses and excluding Inhibigens™, or neoantigens of pro-tumor T...